Compare Amgen, Inc. (AMGN) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Victoria's Secret & Co — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Victoria's Secret & Co trades at $78.36 (market cap $6.23B). The key difference: Amgen, Inc. is far larger — about 31.5× Victoria's Secret & Co's market cap, and Amgen, Inc. pays a 2.77% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| AMGN | VSXY | |
|---|---|---|
Market Cap | $196.12B | $6.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $88.50 |
52-Week Low | $271.18 | $17.70 |
Enterprise Value | $241.41B | $8.87B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Victoria's Secret (VSXY) trades at $78.36, up 2.85% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $75 and resistance at $78. Fundamentally, the company maintains solid revenue around $6.2B with improving net margins, while international growth in China and Europe drives optimism. Analyst consensus is bullish with a $88.56 price target, supported by 55.6% buy ratings.
Outlook remains positive with international expansion and margin recovery as key catalysts, though risks include competitive pressures and execution challenges. The stock offers potential upside to analyst targets but requires monitoring of consumer spending trends and debt levels. Current valuation at P/E 31.22 appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
